On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative.
On Tuesday, April 6th Treatment Action Group (TAG) hosted a webinar for community advocates with a status update on current and future COVID-19 vaccine trials and answers to questions related to safety and efficacy data.
TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for diagnostics as a global norm; and increasing investments in alternative rapid molecular tests to promote competition and improve access.
Join us on March 15, 2021 at 4:00 p.m. EST for this free webinar, which will discuss a variety of issues concerning disenfranchised communities being disproportionately affected by COVID-19.
On February 3, 2021, TAG, Médecins du Monde, hepCoalition, and the UNITE network presented a virtual policy dialogue among policymakers, global civil society organizations, and community leaders who share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.
On Wednesday, February 3, 2021, Treatment Action Group, Médecins du Monde, hepCoalition, and the UNITE network convene a virtual policy dialogue among parliamentarians, global civil society organizations, and community leaders to share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.
This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.
Join TAG and COVID-19 Prevention Network (CoVPN) On Tuesday February 2nd at 4pm ET / 1pm PT, at a webinar for community advocates on COVID-19 outcomes in people living with HIV and implications for COVID-19 vaccines.
TAG is hosting a series of webinars on COVID-19 biomedical prevention research in collaboration with the CoVPN. Information and videos from the first two events may be found on this page.
Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.